6Luks AM, McIntosh SE, Grissom CK, et al. Wilderness medical society consensus guidelines for the prevention and treatment of acute altitude illness[J]. Wilderness Environ Med, 2010, 21(2): 146-155.
7Droma Y, Ge RL, Tanaka M, et al. Acute hypoxie pulmonary vascular response does not accompany plasma endotheliwl elevation in sub jects susceptible to high altitude pulmonary edema[J].Intern IVied 1996, 35(4) : 257-260.
8Pham I, Wuerzner G, Richalet JP, et al. Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans[J]. Eur J Clin Invest, 2010, 40(3): 195-202.
9Barst R J, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary hypertension [J]. Clin Pharmacol Ther, 2003,73(4): 372-382.
10Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phosphodiester ase type 5 and high altitude pulmonary hypertension[J]. Thorax, 2005, 60(8): 683 -687.
10Leon-Velarde F,Maggiorini M ,Reeves JT,et al. Consensus statement on ehronie and subaeute high altitude diseases [J]. High Alt Med Biol, 2005, 6(2): 147 --157.
